Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7261 to 7275 of 7702 results

  1. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Technology appraisal guidance
    Published
    26 October 2016

  2. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy (TA41)

    This guidance has been updated and replaced by NICE technology appraisal guidance 156. 

    Technology appraisal guidance
    Published
    27 May 2002

  3. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  4. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  5. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Medtech innovation briefing
    Published
    26 July 2016

  6. Lutonix drug-coated balloon for peripheral arterial disease (MIB72)

    NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.

    Medtech innovation briefing
    Published
    26 July 2016

  7. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development [GID-TA10886] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    In development [GID-TA11034] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.

    Evidence summary
    Published
    27 June 2017

  10. Smoking: harm reduction (QS92)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Quality standard
    Published
    2 July 2015

  11. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

    Quality standard
    Last updated
    18 August 2016

  12. Glaucoma in adults (QS7)

    This quality standard has been updated and replaced by NICE quality standard 180.

    Quality standard
    Published
    30 March 2011

  13. RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)

    This medtech innovation briefing has been updated and replaced by diagnostics guidance on artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57).

    Medtech innovation briefing
    Published
    1 June 2021

  14. Therapeutic hypothermia following cardiac arrest (IPG386)

    This guidance has been updated and replaced by NICE interventional procedures guidance 782.

    Interventional procedures guidance
    Published
    23 March 2011

  15. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    14 June 2018